Physician profile
Patrick Chen
NPI 1265859243
$29,114.18
in general payments reported to CMS, 2019-2025
22 companies · $9,214 in 2025
The $9,214 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $829 · 2020: $240 · 2021: $417 · 2022: $1,364 · 2023: $15K · 2024: $2,259 · 2025: $9,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Consulting Fee: $8,356 · Food and Beverage: $4,532 · Education: $1,160 · Travel and Lodging: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,969.96 |
| Consulting Fee | $8,356.00 |
| Food and Beverage | $4,531.61 |
| Education | $1,160.00 |
| Travel and Lodging | $246.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $13,869.44 | 2023 | Rebyota |
| Genzyme Corporation | $9,222.14 | 2022-2025 | |
| Abbvie INC. | $2,645.89 | 2021-2025 | Rinvoq, Skyrizi |
| E.R. Squibb & Sons, L.L.C. | $474.82 | 2021-2024 | Zeposia |
| Boston Scientific Corporation | $472.38 | 2022-2025 | Spyglass |
| Pfizer INC. | $344.42 | 2019 | |
| Amgen INC. | $338.30 | 2019-2025 | |
| Qol Medical, LLC | $298.48 | 2021-2024 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $215.21 | 2025 | Tremfya |
| Medtronic, INC. | $192.67 | 2021-2023 | Gi Genius |
| Nestle Healthcare Nutrition INC. | $125.00 | 2023 | |
| Amarin Pharma, INC. | $124.99 | 2019 | |
| Gilead Sciences, INC. | $117.70 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $117.12 | 2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $114.03 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $109.59 | 2024-2025 | Voquezna |
| Lucid Diagnostics INC. | $90.67 | 2022 | |
| Cook Medical LLC | $82.60 | 2019-2025 | Hemospray |
| Sanofi-Aventis U.S. LLC | $67.06 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.05 | 2024 | Entyvio |
| Celgene Corporation | $35.03 | 2022-2023 | Zeposia |
| Celltrion USA INC. | $17.59 | 2025 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.